HC Wainwright & Co. Downgrades Calithera Biosciences to Neutral
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Calithera Biosciences (NASDAQ:CALA) from Buy to Neutral.
William Blair Downgrades Calithera Biosciences to Market Perform
William Blair analyst Matt Phipps downgrades Calithera Biosciences (NASDAQ:CALA) from Outperform to Market Perform.
Why Did Calithera Shares Dropped To 52-Week Low In Premarket Friday?
Calithera Biosciences Inc (NASDAQ:CALA) has decided to terminate its phase 2 KEAPSAKE trial based on a lack of clinical benefit observed…
The Daily Biotech Pulse: NRx’s Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours.
Calithera Posts Early-Data For Arginase Inhibitor In Cystic Fibrosis Trial
Calithera Biosciences Inc (NASDAQ:CALA) shared interim safety and efficacy results from a Phase 1b trial evaluating CB-280, the company’s investigational arginase…
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Calithera Buys Two Oncology Candidates From Takeda For $45M
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK).
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock increased by 28.63% to $5.66 during Monday's after-market session. The market value of their outstanding shares is at $47.1 million.
Calithera Biosciences Reports Purchase Of 2 Clinical-Stage Assets From Takeda Pharma For $10M In Upfront Cash Payment, Up To $35M In Series A Preferred Shares
-- TORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib strengthen Company’s precision oncology pipeline --
-- Calithera will initiate Phase 2 clinical trials of sapanisertib and mivavotinib in 2022